RxDoctor Payments Data

Christina Herald

Optometrist · Fall River, MANPI 1831504133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Coopervision Inc. at 25.3% of the total. Reporting peaked in 2023 at $352 and has fallen 51.7% since, to $170 in 2025.

$663in general payments, 2019–2025

Across 16 payments — averaging $41.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$168
  • Amgen$124
  • Johnson & Johnson Vision Care, Inc.$116
  • Sun Pharmaceutical Industries Inc.$57
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$50
  • Biotissue Holdings Inc.$48
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$663100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$663 in reported general payments places this provider in the 55th percentile of 1,084 optometrist providers in Massachusetts.

See all optometrist providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$48,203
Medicare patients
199
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Restasis MultidoseCyclosporine11$5,489

Paid to pharmacies, not to this prescriber.

Other optometrist in Fall River

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →